Mucosal administration of a chimera composed of Pseudomonas exotoxin and the gp120 V3 loop sequence of HIV-1 induces both salivary and serum antibody responses

Vaccine

Volumn 17, Issue 11-12, 1999, Pages 1425-1433

  Mrsny, Randall J ^a   Daugherty, Ann L ^a   Fryling, Charlotte M ^b   Fitzgerald, David J ^b  

^a GENENTECH INC   (United States)

^b Laboratory of Biochemistry   (United States)

Author keywords

Exotoxin; HIV; Mucosal vaccine; V3 loop

Indexed keywords

EPITOPE; GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; PSEUDOMONAS EXOTOXIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY DETECTION; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGEN PRESENTATION; ARTICLE; BLOOD LEVEL; CHIMERA; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVAGINAL DRUG ADMINISTRATION; MOUSE; MUCOSAL IMMUNITY; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RECTAL DRUG ADMINISTRATION; SALIVA LEVEL; SUBCUTANEOUS DRUG ADMINISTRATION;

ADJUVANTS, IMMUNOLOGIC; ADP RIBOSE TRANSFERASES; AIDS VACCINES; ANIMALS; BACTERIAL TOXINS; EXOTOXINS; FEMALE; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV-1; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; MICE; MICE, INBRED BALB C; PEPTIDE FRAGMENTS; RECOMBINANT FUSION PROTEINS; SALIVA; VIRULENCE FACTORS;

EID: 0033577305     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(98)00380-6     Document Type: Article

References (47)

1. Bomsel M. Transcytosis of infectious human immunodeficiency virus across a tight epithelial cell line barrier. Nat Med. 3:1997;42-47.
2. Bukawa H., Sekigawa K., Hamajima K., Fukushima J., Yamada Y., Kiyono H., Okuda K. Neutralization of HIV-1 by secretory IgA induced by oral immunization with a new macro molecular multicomponent peptide vaccine candidate. Nat Med. 1:1995;681-685.
3. Mazzoli S., Trabattoni D., Lo Caputo S., Piconi S., Blé C., Meacci F., Ruzzante S., Salvi A., Semplici F., Longhi R., Fusi M.L., Tofani N., Biasin M., Villa M.L., Mazzotta F., Clerici M. HIV-specific mucosal and cellular immunity in HIV-seronegative partners of HIV-seropositive individuals. Nat Med. 3:1997;1250-1257.
4. Fowke K., Nagelkerke N.J., Kimani J., Simonson J.N., Anzala A.O., Bwayo J.J., MacDonald K.S., Ngugi E.N., Plummer F.A. Resistance to HIV-1 infection amongst persistently seronegative prostitutes in Nairobi, Kenya. Lancet. 348:1996;1347-1351.
5. + T cell responses associated with control of viremia. Science. 278:1997;1447-1450.
6. Ogg G.S., Jin X., Bonhoeffer S., Dunbar P.R., Nowak M.A., Monard S., Segal J.P., Cao Y., Rowland-Jones S.L., Cerundolo V., Hurley A., Markowitz M., Ho D.D., Nixon D.F., McMichael A.J. Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA. Science. 279:1998;2103-2106.
7. Cease K.B., Berzofsky J.A. Toward a vaccine for AIDS: the emergence of immunobiology-based vaccine development. Ann Rev Immunol. 12:1994;923-989.
8. Ada G.L., McElrath M.J. HIV type 1 vaccine-induced cytotoxic T cell responses: potential role in vaccine efficacy. AIDS Res Hum Retroviruses. 13:1997;205-210.
9. Mestecky J., Jackson S. Reassessment of the impact of mucosal immunity in infection with human immunodeficiency virus (HIV) and design of relevant vaccines. J Clin Immunol. 14:1994;259-272.
10. Haynes B.F., Pantaleo G., Fauci A.S. Toward an understanding of the correlates of protective immunity to HIV infection. Science. 271:1996;324-328.
11. Holmgren J., Czerkinsky C., Lycke N., Svennerholm A.-M. Mucosal immunity: implications for vaccine development. Immunobiol. 184:1992;157-179.
12. McGhee J.R., Xu-Amano J., Miller C.J., Jackson R.J., Fujihashi K., Staats H.F., Kiyono H. The common mucosal immune system: from basic principles to enteric vaccines with relevance for the female reproductive tract. Reprod Fertil Dev. 6:1994;369-379.
13. Santiago N, Haas S, Baughman RA. In: Powell MF, Newman MJ. editors, Vaccine Design: The Subunit and Adjuvant Approach. Plenum Press, New York, 1995. p. 413-438.
14. Mestecky J., Moldoveanu Z., Novak M., Compans R.W. Mucosal immunity and strategies for novel microbial vaccines. Acta Paediatr Jpn. 36:1994;537-544.
15. Kwong P.D., Wyatt R., Robinson J., Sweet R.W., Sodroski J., Hendrickson W.A. Structure of an HIV gp120 envelope glycoprotein in a complex with the CD4 receptor and a neutralizing human antibody. Nat. 393:1998;648-659.
16. Javaherian K., Langlois A.J., McDanal C., Ross K.L., Eckler L.I., Jellis C.L., Profy A.T., Rusche J.R., Bolognesi D.P., Putney S.D., Matthews T.J. Principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein. Proc Natl Acad Sci USA. 86:1989;6768-6772.
17. Cocchi F., DeVico A.L., Garzino-Demo A., Cara A., Gallo R.C., Lusso P. The V3 domain of the HIV-1 gp120 envelope glycoprotein is critical for chemokine-mediated blockade of infection. Nat Med. 2:1996;1244-1247.
18. Valenzuela A., Blance J., Krust B., Franco R., Hovanessian A.G. Neutralizing Antibodies against the V3 loop of human immunodeficiency virus type 1 gp120 block the CD4-dependent and -independent binding of virus to cells. J Virol. 71:1997;8289-8298.
19. Moore J.P., Cao Y., Qing L., Sattentau Q.J., Pyati J., Koduri R., Robinson J., Barbas Iii C.F., Burton D.R., Ho D.D. Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120, and their neutralization is not predicted by studies with monomeric gp120. J Virol. 69:1995;101-109.
20. Ozpolat B., Rao X.M., Powell M.F., Lachman L.B. Immuno liposomes containing antibodies to costimulatory molecules as adjuvants for HIV subunit vaccines. AIDS Res Hum Retroviruses. 14:1998;409-417.
21. FitzGerald DJ, Fryling CM, Vennari JC, Wrin T, Cromwell MEM, Daugherty AL, Mrsny RJ. V3-loop Pseudomonas exotoxin chimeras: characterization of novel candidates for vaccination against human immunodeficiency virus-1. J Biol Chem 1998, submitted.
22. Vasudevachari M.B., Uffelman K.W., Kovacs J., Yeh C.-K., Lane H.C., Salzman N.P. Envelope-specific antibodies in the saliva of individuals vaccinated with recombinant HIV-1 gp160. J Acquired Immune Defic Syndr. 5:1992;817-821.
23. Johansson E.-L., Rask C., Fredrikson M., Eriksson K., Czerkinsky C., Holmgren J. Antibodies and antibody-secreting cells in the female genital tract after vaginal and intranasal immunization with cholera toxin B subunit or conjugates. Infect Immun. 66:1998;514-520.
24. Abbas A.K., Murphy K.M., Sher A. Functional diversity of helper T lymphocytes. Nature. 383:1996;787-793.
25. Vogel FR, Powell MF. In: Powell MF, Newman MJ. editors, Vaccine Design: The Subunit and Adjuvant Approach. Plenum Press, New York, 1995. p. 141-228.
26. MacQueen K.M. The epidemiology of HIV transmission: trends, structure and dynamics. Annu. Rev. Anthropol. 23:1994;509-526.
27. Baba T.W., Trichel A.M., An L., Liska V., Martin L.N., Murphey-Corb M., Ruprecht R.M. Infection and AIDS in adult macaques after nontraumatic oral exposure to cell-free SIV. Science. 272:1996;1486-1489.
28. Neutra M.R., Frey A., Kraehenbuhl J.-P. Epithelial M cells: gateways for mucosal infection and immunization. Cell. 86:1996;345-348.
29. + T cell depletion and viral replication in SIV infection. Science. 280:1998;427-431.
30. Ahlers J.D., Pendleton C.D., Dunlop N., Minassian A., Nara P.L., Berzofsky J.A. Construction of an HIV-1 peptide vaccine containing a multideterminant helper peptide linked to a V3 loop peptide 18 inducing strong neutralizing antibody responses in mice of multiple MHC haplotypes after two immunizations. J Immunol. 150:1993;5647-5665.
31. Gorse G.J., Keefer M.C., Belshe R.B., Matthews T.J., Forrest B.D., Hsieh R.H., Koff W.C., Hanson C.V., Dolin R., Weinhold K.J., Frey S.E., Ketter N., Fast P.E. A dose-ranging study of a prototype synthetic HIV-1MN V3 branched peptide vaccine: the national institute of allergy and infectious diseases AIDS vaccine evaluation group. J Infect Dis. 173:1996;330-339.
32. Fontenot J.D., Gatewood J.M., Mariappan S.V.S., Pau C.-P., Parekh B.S., George J.R., Gupta G. Human immunodeficiency virus (HIV) antigens: Structure and serology of multivalent human mucin MUC1-HIV V3 chimeric proteins. Proc Natl Acad Sci USA. 92:1995;315-319.
33. Wang C.Y., Looney D.J., Li M.L., Walfield A.M., Ye J., Hosein B., Tam J.P., Wong-Staal F. Long-term high-titer neutralizing activity induced by octameric synthetic HIV-1 antigen. Science. 254:1991;285-288.
34. McGhee J.R., Fujihashi K., Xu-Amano J., Jackson R.J., Elson C.O., Beagley K.W., Kiyono H. New perspectives in mucosal immunity with emphasis on vaccine development. Semin Hematol. 30:1993;3-15.
35. Cook J., Barber B.H. Recombinant antibodies with conformationally constrained HIV type 1 epitope inserts elicit glycoprotein 160-specific antibody responses in vivo. AIDS Res Hum Retroviruses. 13:1997;449-460.
36. Haneberg B., Kendall D., Amerongen H.M., Apter F.M., Kraehenbuhl J.-P., Neutra M.R. Induction of specific immunoglobulin A in the small intestine, colon-rectum and vagina measured by a new method for collection of secretions from local mucosal surfaces. Infect Immun. 62:1994;15-23.
37. Kozlowski P.A., Jackson S. Serum IgA subclasses and molecular forms of HIV infection: selective increases in monomer and apparent restriction of the antibody response to IgA1 antibodies mainly directed at env glycoproteins. AIDS Res Hum Retro. 8:1992;1773 - 1780.
38. Gorse G.J., Yang E.Y., Belshe R.B., Berman P.W. Salivary binding antibodies induced by human immunodeficiency virus type 1 recombinant gp120 vaccine. Clin Diagnostic Lab Immunol. 3:1996;769-773.
39. Hilleman M.R. Impediments, imponderables and alternatives in the attempt to develop an effective vaccine against AIDS. Vaccine. 10:1992;1053-1058.
40. Belyakov I.M., Derby M.A., Ahlers J.D., Kelsall B.L., Earl P., Moss B., Strober W., Berzofsky J.A. Mucosal immunization with HIV-1 peptide vaccine induces mucosal and systemic cytotoxic T lymphocytes and protective immunity in mice against intrarectal recombinant HIV-vaccinia challenge. Proc Natl Acad Sci USA. 95:1998;1709-1714.
41. Funkhouser A., Clements M.L., Slome S., Clayman B., Viscidi R. Antibodies to recombinant gp160 in mucosal secretions and sera of persons infected with HIV-1 and seronegative vaccine recipients. AIDS Res Hum Retroviruses. 9:1993;627-632.
42. Connor R.I., Korber B.T.M., Graham B.S., Hahn B.H., Ho D.D., Walker B.D., Neumann A.U., Vermund S.H., Mestecky J., Jackson S., Fenamore E., Cao Y., Gao F., Kalams S., Kunstman K.J., McDonald D., McWilliams N., Trkola A., Moore J.P., Wolinsky S.M. Immunological and virological analysis of persons infected by human immunodeficiency virus type 1 while participating in trials of recombinant gp120 subunit vaccines. J Virol. 72:1998;1552-1576.
43. Lehner T., Bergmeier L.A., Panagiotidi C., Tao L., Brookes R., Klavinskis L.S., Walker P., Walker J., Ward R.G., Hussain L., Gearing A.J.H., Adams S.E. Induction of mucosal and systemic immunity to a recombinant simian immunodeficiency viral protein. Science. 258:1992;1365-1369.
44. Roberts M., Bacon A., Rappuoli R., Pizza M., Cropley I., Douce G., Dougan G., Marinaro M., McGhee J., Chatfield S. A mutant pertussis toxin molecule that lacks ADP-ribosyltransferase activity, PT-9K/129G, is an effective mucosal adjuvant for intranasally delivered proteins. Infect Immun. 63:1995;2100-2108.
45. Lukac M., Pier G.B., Collier R.J. Toxoid of Pseudomonas aeruginosa exotoxin A generated by deletion of an active site residue. Infect Immun. 56:1988;3095-3098.
46. Ogata M., Fryling C.M., Pastan I., FitzGerald D.J. Cell-mediated cleavage of Pseudomonas exotoxin between Arg279 and Gly280 generates the enzymatically active fragment which translocates to the cytosol. J Biol Chem. 267:1992;25395-25401.
47. 2-macroglobulin receptor/low density lipoprotein receptor-related protein binds and internalizes Pseudomonas exotoxin. AJ Biol Chem. 267:1992;12420-12423.